,19,20 NIR-PIT has shown therapeutic efficacy against several cancer types by targeting antigens such as epidermal growth factor receptor1 (EGFR), human epidermal growth factor receptor 2 (Her2), carcinoembryonic antigen (CEA), and prostate-specific membrane antigen (PSMA).20 Here, FOLH1 is linked to cancer.